« Return to News | Awards & Advancement

NIH awards Avaxia Biologics $1.5 million for bowel disease

Monday, March 19, 2012 10:57 AM

Avaxia Biologics, a privately-held biotech company based in Lexington, Mass., has received a second round of funding from the National Institutes of Health (NIH) to develop orally-active antibody therapeutics for the treatment of inflammatory bowel disease (IBD).

The phase II Small Business Innovation Research (SBIR) grant was awarded to Avaxia by a branch of NIH, the National Institute of Diabetes and Digestive and Kidney Diseases. The grant awards $1.5 million in funding over two years and was based on the successful completion of a phase I SBIR award that demonstrated efficacy of AVX-470 in mouse model systems of inflammatory bowel disease.

"Generated under prior funding of the NIH, our orally active anti-TNF antibody significantly reduced inflammatory bowel disease severity in three different animal models and showed superior efficacy to an oral steroid drug in a comparative test of disease remission,” said Barbara S. Fox, founder and CEO, Avaxia. “With these impressive results, and with the support of this phase II SBIR grant, Avaxia plans to enter into clinical trials with AVX-470 in patients with IBD this year. AVX-470 appears to be on track to be the first orally-active anti-TNF antibody for IBD."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.